Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

Eikon Therapeutics shared new clinical data from its pipeline at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO). The Phase 2 TeLuRide-005 trial of EIK1001, a dual-agonist targeting Toll-like receptors 7 and 8, completed enrollment for 72 first-line stage 4 NSCLC patients. By May 4, 2026, the combination of EIK1001 with pembrolizumab and chemotherapy showed a 63.1% objective response rate (ORR) and 90.8% disease control rate (DCR), with non-squamous patients achieving a 55.6% ORR and 83.3% DCR. The treatment was generally well-tolerated, with most adverse events (AEs) being Grade 1-2. Grade 3 or higher treatment-related AEs included neutropenia (30.6%), anemia (9.7%), and thrombocytopenia (9.7%). Cytokine release syndrome (CRS) events were mild (Grade 1-2) and occurred early in treatment, supporting outpatient administration. EIK1001’s mechanism complements PD-(L)1 blockade, potentially enhancing antitumor immune responses. Additionally, Eikon presented updated Phase 1/2 data for EIK1003, showing monotherapy efficacy and initial combination results with weekly paclitaxel in advanced solid tumors. Responses were observed even in heavily pretreated patients, suggesting potential for broader clinical utility. Roy Baynes, M.D., Ph.D., Chief Medical Officer, highlighted the progress, noting the growing evidence supporting Eikon’s lead programs. The findings reinforce the scientific rationale behind Eikon’s approach, aiming to deliver meaningful benefits to cancer patients. The data will be further analyzed as the trials continue, with EIK1001’s maximum treatment duration set at two years. Eikon’s ASCO presentation included six abstracts, reflecting advancements across its pipeline.